Amarin Reports (REDUCE-IT) Study Results of Vascepa/Vazkepa (icosapent ethyl) for Acute Coronary Syndrome Event
- The company highlighted the new analysis from the (REDUCE-IT) study evaluating Vascepa/Vazkepa (icosapent ethyl) vs PBO in patients with recent acute coronary syndrome
- In the post-hoc analysis, icosapent ethyl (IPE) showed a significant reduction in risk of first and total ischemic events by 37% & 36% in patients with recent ACS without increasing bleeding supporting early initiation of IPE after ACS
- Absolute risk reduction for first events with IPE treatment over 5yrs. for the primary composite EPs & in patients with ACS ≥12mos. was 9.3% & 4.7% with an NNT of 11 & 21. Overall tolerability and AEs were consistent with the full study
Ref: Globenewswire | Image: Amarin
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.